Diphtheria, Tetanus Toxoids, and Acellular Pertussis Vaccine and Haemophilus influenzae b Conjugate Vaccine

Pronunciation

(dif THEER ee a, TET a nus TOKS oyds & ay CEL yoo lar per TUS sis vak SEEN & hem OF fi lus in floo EN za bee KON joo gate vak SEEN)

U.S. Brand Names

TriHIBit®

Synonyms

Haemophilus influenzae b Conjugate Vaccine and Diphtheria, Tetanus Toxoids, and Acellular Pertussis Vaccine

Generic Available

No

Use

Active immunization of children 15-18 months of age for prevention of diphtheria, tetanus, pertussis, and invasive disease caused by H. influenzae type b.

Contraindications

Any contraindication of the component vaccines (see individual agents); contraindicated in children <15 months of age

Dosage

Children >15 months of age: I.M.: 0.5 mL (as part of a general vaccination schedule; see individual vaccines). Vaccine should be used within 30 minutes of reconstitution.

Administration

For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends "it should be administered intramuscularly if, in the opinion of the physician familiar with the patients bleeding risk, the vaccine can be administered with reasonable safety by this route. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection."

Additional Information

TriHIBit® is Tripedia® vaccine used to reconstitute ActHIB® (Haemophilus b conjugate) vaccine. The combination can be used for the DTaP dose given at 15-18 months when Tripedia® was used for the initial doses and a primary series of HIB vaccine has been given. Federal law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title and address be entered into the patient's permanent medical record.

Dental Health: Effects on Dental Treatment

No significant effects or complications reported

Dental Health: Vasoconstrictor/Local Anesthetic Precautions

No information available to require special precautions

Dosage Forms

Injection, suspension: 5 Lf units tetanus toxoid, 6.7 Lf units diphtheria toxoid, 46.8 mcg pertussis antigens, and 10 mcg H. influenzae type b purified capsular polysaccharide per 0.5 mL (0.5 mL) [The combination of Tripedia® vaccine used to reconstitute ActHIB® forms TriHIBit®]

References

Centers for Disease Control, "Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,"MMWR Recomm Rep, 1994, 43(RR-1):23.